UK Yanks 16 of Wockhardt's Drugs for Production Failures

Published: Jul 12, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Britain's MHRA drug regulator has halted the sale of 16 medicines made by Wockhardt after it identified manufacturing deficiencies at the Indian group's Waluj factory. Though the Medicines and Healthcare products Regulatory Agency said there is no evidence that the products are defective and that patients who already have the medicines do not need to return them, pharmacies, dispensing clinics and wholesalers have been asked to stop selling them. "This is not a patient-level recall because, though the medicines that are affected have not been manufactured to Good Manufacturing Practice (GMP) standards, there is no evidence of a patient safety risk from medicines that have been sold in the UK," the agency said on Thursday. "However, the MHRA has to act in the interests of public health as poor manufacturing standards cannot be allowed to continue."

Help employers find you! Check out all the jobs and post your resume.

Back to news